omniture
logo
Search
应世生物科技（上海）有限公司 INXMED
Media Room

Latest News

rss

InxMed Announces Promising Phase Ib/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025

NANJING, China, June 1, 2025 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnological com...

2025-06-01 15:00 2228

InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

NANJING, China, Nov. 21, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compa...

2024-11-21 15:09 5728

InxMed Presents Data regarding Potential Novel Way to Improve Therapeutic Window of ADC by Ifebemtinib and FIC ADC at 15th Annual World ADC

NANJING, China, Nov. 7, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compan...

2024-11-08 10:40 1987

InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs

NANJING, China, Dec. 19, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedica...

2023-12-20 09:00 2186

InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023

NANJING, China, Oct 22, 2023 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compan...

2023-10-23 08:00 2170

InxMed Presents New Data at 14th Annual World ADC Highlighting Synergy of IN10018 with ADCs and Novel Stroma targeting pipeline

NANJING, China, Oct. 18, 2023 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compa...

2023-10-19 08:00 1914

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC

NANJING, China, Aug. 29, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedica...

2023-08-30 11:00 2336

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022

NANJING, China, Oct. 17, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compa...

2022-10-18 08:00 1484

InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer

NANJING, China, Sept. 7, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compa...

2022-09-08 08:00 1838

InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients with platinum-resistant recurrent ovarian cancer

NANJING, China, May 29, 2022  /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compa...

2022-05-30 08:10 2202

InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers

NANJING, China, May 8, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company...

2022-05-09 08:04 2107

InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy Designation by the China National Medical Products Administration for Platinum-Resistant Ovarian Cancer

NANJING, China, April 13, 2022 /PRNewswire/ -- InxMed Co., Ltd. announced that IN0018, its focal a...

2022-04-14 08:00 2379

InxMed Raised $50 million in Series B Financing to Advance Innovative Therapies to Drug-resistance Cancers

NANJING, China, March 3, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compa...

2022-03-04 08:00 2066

InxMed's IN10018 Receives U.S. FDA Fast Track Designation for the Treatment of Platinum-resistant Ovarian Cancer

NANJING, China, Aug. 15, 2021 /PRNewswire/ -- InxMed (Nanjing) Co., Ltd. ("InxMed" or "Company"), ...

2021-08-16 09:31 1769

Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer

SHANGHAI, June 25, 2021 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clin...

2021-06-25 15:06 1711